NKTR - nektar.com Market Value to Book Value Ratio
Nektar Therapeutics (NKTR) relies on modern US R&D centers, outsourcing mass drug manufacturing to certified third-party contractors. This price chart on the GURU.Markets platform is currently at 1.48. The implementation of AI and robotics is accelerating the discovery of new molecules, although final trials remain the responsibility of humans. Biotech laboratories operate without equipment depreciation thanks to the regular modernization of synthesis lines.
Nektar Therapeutics Inc (NKTR) - metric breakdowns and financial figures
- market value and analyst target forecast:
- market capitalization statistics:
- book capitalization data:
- debt obligations and liquidity statistics:
- earnings and valuation multiples indicators:
Basic company analysis:Nektar Therapeutics - NKTR
The stability of the immuno-oncology platform of Nektar Therapeutics (NKTR), supported by a partner-based development model and a strong balance sheet, minimizes risks during market volatility. By analyzing the price-to-book ratio, an investor assesses the market premium over net assets, where a deviation from unity signals an overvaluation or undervaluation of the business relative to its intrinsic value.
Competitor analysis
argenx SE (ARGX) - Market Value to Book Value Ratio|biontech.de - Market Value to Book Value|Market Value to Book Value Ratio abivax.com|ADMA Biologics Inc - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio PTGX|IMVT (Immunovant Therapeutics) - Market Value to Book Value|Market Capitalization to Book Value Ratio KNSA (Kiniksa Pharmaceuticals)|Market Capitalization to Book Value Ratio grifols.com GRFS|ADPT - Market Value to Book Value Ratio|Market Value to Book Value CLDX (Celldex Therapeutics Inc)|Aurinia Pharma (AUPH) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio BioCryst Corp|VERA (Vera Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio dianthustx.com|Market Cap to Net Assets Ratio PHVS (Pharvaris)|ABCL (AbCellera Biologics) - Market Value to Book Value|Market Capitalization to Book Value Ratio TRML (Tourmaline Corp)|Market Capitalization to Book Value Precigen Corp (PGEN)|PHAR - Market Value to Book Value Ratio|upstreambio.com (UPB) - Market Cap to Net Assets Ratio|Zenas Biopharma (ZBIO) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Immunome Inc|Market Cap to Net Assets Ratio GOSS|Market Capitalization to Book Value Ratio KalVista Corp|Market Value to Book Value Ratio Septerna Inc (SEPN)|pieris.com - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio SVRA (Savara)|Rigel Pharma (RIGL) - Market-to-Book Ratio|ANAB - Market Value to Book Value Ratio|ATXS (Astria Corp) - Capitalization to Book Value Ratio|ENGN: Market Capitalization to Book Value Ratio|Market-to-Book Ratio rapt.com (RAPT)|Market Value to Book Value Ratio Aerovate Therapeutics, Inc.|Market Capitalization to Book Value Ratio Aclaris Therapeutics Inc.|Market Cap to Net Assets Ratio KYTX (Kyverna)|Market Cap to Book Value Multiple TLSA|Market Capitalization to Book Value Ratio CABA (Cabaletta Bio, Inc.)|Market Capitalization to Book Value Ratio ventyxbio.com VTYX|THTX - Market Value to Book Value Ratio|Market Value to Book Value AVTX (Avalo Therapeutics, Inc.)|ELDN (Eledon) - Market Cap to Net Assets Ratio|Agenus, Inc - Market Value to Book Value|Market Cap to Net Assets Ratio CLYM|ZURA (zurabio.com) - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio ATYR|ADAG (adagene.com) - Market Value to Book Value|Market Capitalization to Book Value Ratio IMA (Ikena Oncology)|Shattuck Labs Inc (STTK) - Market-to-Book Ratio|EQ - Market Value to Book Value Ratio|Market Value to Book Value CNTB (Connect Biopharma)|IMUX: Market Capitalization to Book Value Ratio|Atara Bio (ATRA) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio InflaRx NV|X4 Pharmaceuticals, Inc - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio ACET|CELU - Market-to-Book Ratio|INmune Bio - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio Barinthus Biotherapeutics PLC BRNS|KZR: Market Cap to Net Assets Ratio|SAB Biotherapeutics Inc - Market Cap to Book Value Multiple|AKTX: Market Capitalization to Book Value Ratio|ENLV - Market Capitalization to Book Value|QTTB (Q32 Bio Inc) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio GeoVax Labs (GOVX)|Market Value to Book Value Ratio Edesa (EDSA)|Market Capitalization to Book Value iBio Corporation|Market Value to Book Value Ratio Carisma Therapeutics Inc. CARM|XTLB: Capitalization to Book Value Ratio|BOLT - Market Value to Book Value Ratio|HCWB - Market Capitalization to Book Value Ratio|APVO (aptevotherapeutics.com) - Market Cap to Net Assets Ratio|AIM: Market Cap to Book Value Multiple|Market Value to Book Value Ratio Aditxt Inc.|GRI: Market Value to Book Value|Market Value to Book Value Ratio XORTX Therapeutics (XRTX)|HIND: Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio REVB (Revelation Bio)|Market Value to Book Value INDP|Scinai Immunotherapeutics - Market Capitalization to Book Value Ratio|CALI - Market Capitalization to Book Value Ratio|affimed.com (AFMD) - Market Value to Book Value Ratio|Allakos - Market Value to Book Value|Market Value to Book Value Ratio HOOKIPA Pharma, Inc.|Market Cap to Net Assets Ratio IGM Bio (IGMS)|Market Capitalization to Book Value Ratio ITOS|Market Capitalization to Book Value Ratio oceanbiomedical.com (OCEA)|TC BioPharm - Market Cap to Net Assets Ratio|Market Value to Book Value THRD